Key Highlights

  • NextCure shares closed up 202% at $6.58 after finalizing a definitive all-stock reverse merger with Avere Therapeutics, forming a clinical-stage entity trading as Avere Therapeutics (NASDAQ: AVRX).
  • The reorganized firm, guided by CEO Dr. Andrew Cheng, will focus on AVR-001, a long-acting IL-23 receptor antagonist licensed from Hansoh Pharma.
  • Avere stockholders will hold approximately 98.79% ownership of the combined company, while NextCure holders retain 1.21% plus a two-year contingent value right (CVR) for 90% of proceeds from legacy assets.
  • The deal is backed by a $320 million private placement led by Fairmount and Hansoh, extending the combined company's operational runway through key 2028 clinical milestones.

NextCure, Inc. (NASDAQ: NXTC) shares surged 202% to close at $6.58 after the company finalized a definitive all-stock reverse merger with Avere Therapeutics, creating a new clinical-stage entity that will trade under the ticker Avere Therapeutics (NASDAQ: AVRX). The scale of today's move reflects how dramatically the market is repricing NextCure's equity in light of the new pipeline and financing it now carries.

The combined company will be guided by CEO Dr. Andrew Cheng and will prioritize AVR-001, a long-acting cyclic peptide IL-23 receptor antagonist licensed from Hansoh Pharma. Reverse mergers of this kind allow private companies like Avere to gain public market access by combining with an already-listed company, a structure that has become increasingly common for biotechs seeking public capital markets exposure without pursuing a traditional IPO.

The ownership split underscores which side of the transaction the market views as the primary value driver: Avere stockholders will hold approximately 98.79% of the combined company, while legacy NextCure stockholders retain a much smaller 1.21% stake. To offset this dilution, NextCure holders also receive a two-year contingent value right (CVR) entitling them to 90% of any proceeds realized from NextCure's legacy pipeline assets, a mechanism that preserves some economic upside without requiring the new company to prioritize those older programs.

Underpinning the transaction is a $320 million private placement led by Fairmount and Hansoh Pharma, the same company licensing AVR-001 to Avere. Hansoh's dual role as both licensor and lead investor signals a strong alignment of interest in the combined company's success, lending additional credibility to the deal's underlying science.

This capital is expected to fund the combined company through key milestones, including a Phase 2b psoriasis readout expected in early 2028 and the commencement of a separate Phase 2b trial in ulcerative colitis. Having this level of visibility into funded, multi-year clinical catalysts appears to be a central factor behind today's dramatic share price reaction, as investors reprice NextCure's essentially shell-like prior valuation against the new pipeline, financing, and leadership now attached to the stock.

For a stock that had previously traded well below the levels seen today, this kind of reverse merger repricing is a common pattern when a struggling public company's own pipeline value is effectively replaced by a well-funded private company's assets and cash. Investors will now shift their focus toward Avere's execution on AVR-001's clinical program as the primary driver of the newly formed company's valuation going forward.